Vaccines Europe: Presentations You Won’t Want to Miss
Find out about some of Oxford Global’s most highly anticipated presentations happening at our upcoming Vaccines Congress.
Next week, Oxford Global’s Vaccines Europe: In-Person event will be taking place in Berlin. The congress will include an engaging range of presentations looking at modern vaccine platform technologies, vaccine development, and applications of vaccines in therapeutics. In the lead-up to the event, we take a look at three presentations which we’re sure you won’t want to miss.
1. Lab to Jab in 100 Days: Manufacturing Flexibility for Future Rapid Response
The Coalition for Epidemic Preparedness Innovations (CEPI) recently announced its ambition to develop vaccines against emerging diseases in 100 days. mRNA vaccines are one of the manufacturing modalities best suited to meet the 100-day strategy.
Thanks to the flexibility, cost, and speed of development, mRNA vaccine technology offers great benefits and potential for infectious diseases and personalised medicines. However, there are still several barriers that researchers need to overcome to realise these vaccines’ full potential.
Katarina Stenklo, Commercial Activation and End-to-End Solutions Leader at Cytiva, will discuss both the immense potential of mRNA vaccine technology and how manufacturers can better prepare for rapid response.
2. Top-Of-Mind or Forgotten – What Impact Will the Pandemic Have in the Vaccination Market?
Over the course of the COVID-19 pandemic, hearing about vaccines and vaccine development was unavoidable. But as we move beyond COVID and try to return to “normal”, where will this leave vaccines in the world’s agenda? Top-of-mind or forgotten altogether?
Ali Ciger, Country Lead for Vaccines at Pfizer, will consider how the increased attention given to vaccines in the global mind over the past two years will manifest for key stakeholders in the vaccine market, from the decisions taken by regulators and producers to the impact this will have on public and prescribers.
3. Profiling Influenza Vaccine Responses in the Elderly
Not all vaccines are high responders, but this does not necessarily mean that they are without use. In this presentation, Carlos Guzman, Head of the Department of Vaccinology & Applied Microbiology at the Helmholtz Centre for Infection Research, ponders what we might be able to learn from the variety of responses we see with different vaccines.
Guzman will explore several questions regarding how influenza vaccine responses in the elderly can be profiled. Amongst these, he will examine whether in-depth immune profiling flanked by multi-Omics may help our understanding of vaccine responses, and whether we might be able to dissect underlying molecular pathways. He will also discuss the possibility that vaccination networks may be able to lead to predictive biomarkers.
Join Oxford Global’s annual Biologics UK: In-Person event today. This 3-day conference brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and exciting industry outlooks.
Get your weekly dose of industry news here and keep up to date with the latest ‘Industry Spotlight’ posts. For other Biologics content, please visit the Biologics Content Portal.
